Univariate analysis of PFS or overall survival in patients with HIV-DLBCL
| . | Overall survival . | PFS . | Death or progression . | P value (log-rank) . | Missing . |
|---|---|---|---|---|---|
| N | 40 | 26 | 14 | ||
| Demographics | |||||
| Age >50 y | 20 (50.0) | 14 (53.8) | 6 (42.9) | 0.60 | 0 |
| Sex (male) | 35 (87.5) | 23 (88.5) | 12 (85.7) | 0.87 | 0 |
| HIV infection | |||||
| Ongoing cART | 35 (87.5) | 23 (88.5) | 12 (85.7) | 0.99 | 0 |
| New HIV diagnosis | 4 (10.3) | 4 (15.4) | 0 (0.0) | 0.15 | 1 |
| AIDS stage | 14 (35.0) | 11 (42.3) | 3 (21.4) | 0.23 | 0 |
| Active HIV replication (>200/mL) | 14 (35.0) | 8 (30.8) | 6 (42.9) | 0.45 | 0 |
| Positive HCV serological test | 13 (34.2) | 7 (29.2) | 6 (42.9) | 0.32 | 2 |
| Lymphoma | |||||
| PS ≥ 2 | 15 (37.5) | 6 (23.1) | 9 (64.3) | < 0.01 | 0 |
| Elevated LDH | 20 (51.3) | 11 (44.0) | 9 (64.3) | 0.32 | 1 |
| Lymphoma stage | 0.20 | 0 | |||
| I-II | 4 (10.0) | 4 (15.4) | 0 (0) | ||
| III-IV | 36 (90.0) | 22 (84.6) | 14 (100.0) | ||
| R-IPI score | 0.049 | 0 | |||
| Very good | 2 (5.0) | 2 (7.7) | 0 (0.0) | ||
| Good | 20 (50.0) | 16 (61.5) | 4 (28.6) | ||
| Poor | 18 (45.0) | 8 (30.8) | 10 (71.4) | ||
| Germinal center phenotype | 13 (35.1) | 9 (39.1) | 4 (28.6) | 0.70 | 3 |
| Bcl2 expression | 18 (60.0) | 8 (44.4) | 10 (83.3) | 0.07 | 10 |
| Bcl6 expression | 20 (69.0) | 12 (70.6) | 8 (66.7) | 0.77 | 11 |
| LMP expression | 2 (15.4) | 1 (12.5) | 1 (20.0) | 0.65 | 27 |
| EBER | 6 (18.2) | 5 (22.7) | 1 (9.1) | 0.38 | 7 |
| Immunoglobulin | |||||
| IgG <10 g/L | 10 (25.6) | 4 (16.0) | 6 (42.9) | 0.095 | 1 |
| IgA <1 g/L | 3 (7.7) | 1 (4.0) | 2 (14.3) | 0.28 | 1 |
| IgM <1 g/L | 19 (48.7) | 11 (44.0) | 8 (57.1) | 0.58 | 1 |
| T lymphocytes | |||||
| CD3+CD4+ T lymphocytes <0.2 × 109/L | 16 (41.0) | 10 (40.0) | 6 (42.9) | 0.66 | 1 |
| CD3+CD8+ T lymphocytes <0.5 × 109/L | 17 (43.6) | 10 (40.0) | 7 (50.0) | 0.65 | 1 |
| B lymphocytes | |||||
| CD19+ B lymphocytes <0.050 × 109/L | 16 (41.0) | 9 (36.0) | 7 (50.0) | 0.35 | 1 |
| CD19+CD27−IgD+ among B cells >50% | 23 (71.9) | 18 (85.7) | 5 (45.5) | 0.017 | 8 |
| CD19+CD27+IgD+ among B cells >5% | 16 (50.0) | 9 (42.9) | 7 (63.6) | 0.29 | 8 |
| CD19+CD27+IgD− among B cells >10% | 17 (53.1) | 10 (47.6) | 7 (63.6) | 0.38 | 8 |
| NK lymphocytes | |||||
| NK lymphocytes <0.05 × 109/L | 10 (25.6) | 2 (8.0) | 8 (57.1) | 0.001 | 1 |
| Cytokines | |||||
| IL-6 > 20 pg/mL | 13 (33.3) | 5 (20.0) | 8 (57.1) | 0.011 | 1 |
| IL-10 > 20 pg/mL | 24 (60.0) | 16 (61.5) | 8 (57.1) | 0.77 | 0 |
| BAFF > 20 pg/mL | 19 (50.0) | 10 (41.7) | 9 (64.3) | 0.17 | 2 |
| . | Overall survival . | PFS . | Death or progression . | P value (log-rank) . | Missing . |
|---|---|---|---|---|---|
| N | 40 | 26 | 14 | ||
| Demographics | |||||
| Age >50 y | 20 (50.0) | 14 (53.8) | 6 (42.9) | 0.60 | 0 |
| Sex (male) | 35 (87.5) | 23 (88.5) | 12 (85.7) | 0.87 | 0 |
| HIV infection | |||||
| Ongoing cART | 35 (87.5) | 23 (88.5) | 12 (85.7) | 0.99 | 0 |
| New HIV diagnosis | 4 (10.3) | 4 (15.4) | 0 (0.0) | 0.15 | 1 |
| AIDS stage | 14 (35.0) | 11 (42.3) | 3 (21.4) | 0.23 | 0 |
| Active HIV replication (>200/mL) | 14 (35.0) | 8 (30.8) | 6 (42.9) | 0.45 | 0 |
| Positive HCV serological test | 13 (34.2) | 7 (29.2) | 6 (42.9) | 0.32 | 2 |
| Lymphoma | |||||
| PS ≥ 2 | 15 (37.5) | 6 (23.1) | 9 (64.3) | < 0.01 | 0 |
| Elevated LDH | 20 (51.3) | 11 (44.0) | 9 (64.3) | 0.32 | 1 |
| Lymphoma stage | 0.20 | 0 | |||
| I-II | 4 (10.0) | 4 (15.4) | 0 (0) | ||
| III-IV | 36 (90.0) | 22 (84.6) | 14 (100.0) | ||
| R-IPI score | 0.049 | 0 | |||
| Very good | 2 (5.0) | 2 (7.7) | 0 (0.0) | ||
| Good | 20 (50.0) | 16 (61.5) | 4 (28.6) | ||
| Poor | 18 (45.0) | 8 (30.8) | 10 (71.4) | ||
| Germinal center phenotype | 13 (35.1) | 9 (39.1) | 4 (28.6) | 0.70 | 3 |
| Bcl2 expression | 18 (60.0) | 8 (44.4) | 10 (83.3) | 0.07 | 10 |
| Bcl6 expression | 20 (69.0) | 12 (70.6) | 8 (66.7) | 0.77 | 11 |
| LMP expression | 2 (15.4) | 1 (12.5) | 1 (20.0) | 0.65 | 27 |
| EBER | 6 (18.2) | 5 (22.7) | 1 (9.1) | 0.38 | 7 |
| Immunoglobulin | |||||
| IgG <10 g/L | 10 (25.6) | 4 (16.0) | 6 (42.9) | 0.095 | 1 |
| IgA <1 g/L | 3 (7.7) | 1 (4.0) | 2 (14.3) | 0.28 | 1 |
| IgM <1 g/L | 19 (48.7) | 11 (44.0) | 8 (57.1) | 0.58 | 1 |
| T lymphocytes | |||||
| CD3+CD4+ T lymphocytes <0.2 × 109/L | 16 (41.0) | 10 (40.0) | 6 (42.9) | 0.66 | 1 |
| CD3+CD8+ T lymphocytes <0.5 × 109/L | 17 (43.6) | 10 (40.0) | 7 (50.0) | 0.65 | 1 |
| B lymphocytes | |||||
| CD19+ B lymphocytes <0.050 × 109/L | 16 (41.0) | 9 (36.0) | 7 (50.0) | 0.35 | 1 |
| CD19+CD27−IgD+ among B cells >50% | 23 (71.9) | 18 (85.7) | 5 (45.5) | 0.017 | 8 |
| CD19+CD27+IgD+ among B cells >5% | 16 (50.0) | 9 (42.9) | 7 (63.6) | 0.29 | 8 |
| CD19+CD27+IgD− among B cells >10% | 17 (53.1) | 10 (47.6) | 7 (63.6) | 0.38 | 8 |
| NK lymphocytes | |||||
| NK lymphocytes <0.05 × 109/L | 10 (25.6) | 2 (8.0) | 8 (57.1) | 0.001 | 1 |
| Cytokines | |||||
| IL-6 > 20 pg/mL | 13 (33.3) | 5 (20.0) | 8 (57.1) | 0.011 | 1 |
| IL-10 > 20 pg/mL | 24 (60.0) | 16 (61.5) | 8 (57.1) | 0.77 | 0 |
| BAFF > 20 pg/mL | 19 (50.0) | 10 (41.7) | 9 (64.3) | 0.17 | 2 |
The results are presented as n (%). Statistical analyses were conducted using survival analysis (Kaplan Meier estimate and log-rank test).
EBER, Ebstein-Barr virus encoded small RNAs; HCV, hepatitis C virus; LDH, lactate dehydrogenase; LMP, latent membrane protein.